Last reviewed · How we verify
MVA-BN half-dose regimen
MVA-BN is a modified vaccinia Ankara-based vaccine expressing monkeypox antigens that primes the immune system to recognize and respond to monkeypox virus infection.
MVA-BN is a modified vaccinia Ankara-based vaccine expressing monkeypox antigens that primes the immune system to recognize and respond to monkeypox virus infection. Used for Monkeypox (mpox) prevention in adults at risk of exposure.
At a glance
| Generic name | MVA-BN half-dose regimen |
|---|---|
| Sponsor | Jean-Pierre Van geertruyden |
| Drug class | Live attenuated viral vaccine |
| Target | Monkeypox virus antigens (L1, A29, I3, I4, I5 proteins) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
MVA-BN is a live, attenuated viral vaccine vector derived from vaccinia virus that has been engineered to express immunogenic proteins from monkeypox virus. The half-dose regimen reduces the vaccine dose while maintaining immunogenicity, potentially improving tolerability and expanding vaccine supply. It works by stimulating both cellular and humoral immune responses against monkeypox antigens.
Approved indications
- Monkeypox (mpox) prevention in adults at risk of exposure
Common side effects
- Injection site reaction (erythema, swelling, pain)
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MVA-BN half-dose regimen CI brief — competitive landscape report
- MVA-BN half-dose regimen updates RSS · CI watch RSS
- Jean-Pierre Van geertruyden portfolio CI